Gilead Sciences partners with Vir Biotechnology to advance multi-program solid tumor therapies

Gilead Sciences partners with Vir Biotechnology to advance multi-program solid tumor therapies
Vir, Gilead in cancer partnership

Vir Biotechnology has announced a multi-program collaboration and license agreement with Gilead Sciences focusing on the discovery and engineering of novel PRO-XTEN dual-masked T-cell engagers (TCEs) for multiple solid tumor indications.

The partnership aims to leverage both companies' expertise to advance innovative immuno-oncology therapeutics for treatment of solid tumors. The agreement indicates both a broadening of Vir Biotechnology's oncology portfolio and Gilead Sciences' continued investment in next-generation cancer therapies.

Vir Biotechnology recently appointed David Liu as executive vice president and chief medical officer to leverage his immuno-oncology and regulatory expertise for upcoming therapies, as reported here. The company also named Aziz Sawaf as executive vice president and CFO, with responsibilities spanning finance, operations, IT, and investor relations, according to a previous announcement. These leadership moves signal a focus on expanding Vir's capabilities in oncology and corporate management.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.